Study of TRB-061 for atopic dermatitis (eczema)
Part of Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You weigh at least 110 pounds (50 kg) and have a BMI between 18.5 and 35.
- You are in generally good health, based on your medical history and tests.
- If you have eczema, it must be moderate to severe and have started at least 1 year ago.
- You do not have active infections like tuberculosis, hepatitis B or C, or HIV.
- You have not used certain immune-suppressing drugs or participated in another drug trial recently.
- You agree to not use marijuana (THC) products during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called HXN5003 to see if it is safe and how well it works for people with moderate-to-severe eczema (atopic dermatitis). It may help reduce symptoms like itching and rash.
This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
This study tests a new investigational drug, called HRS-8797, in healthy people to see how safe it is and how the body processes it. It's an early-phase trial, so you may not directly benefit, but your participation can help find new treatments for future patients.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.